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Abstract
Background: Cognitive reserve is thought to influence the degree of neuropathology needed for
diagnosis of Alzheimer disease (AD). Cognitive reserve can be operationally defined as the
hypothesized capacity of the mature adult brain to sustain the effects of disease or injury without
manifesting clinical symptoms of AD, but sufficient to cause clinical dementia in an individual
possessing less cognitive reserve. Its effect on the subsequent course of AD is less clear. Pre-
morbid IQ is a useful measure of cognitive reserve.
Methods: We studied 659 consecutive patients with AD at a tertiary referral memory clinic.
Patients were assessed on six cognitive tests at baseline. Activities of Daily Living (ADL) were
measured on the Instrumental Activities of Daily Living (IADL) scale and Physical Self-Maintenance
Scale (PSMS). The National Adult Reading Test (NART) was used to estimate pre-morbid IQ.
Patients were followed up after starting a cholinesterase inhibitor over 78 weeks. Mixed general
linear models estimated the effects of NART on cognition and ADL.
Results: Three hundred and fifty-five patients had NART scored with a mean estimated pre-
morbid IQ of 104.7 (standard deviation 18.5). NART increased overall cognitive ability by 2.7% for
every 10 IQ points (p < .001). There was a trend for an effect on the change in cognition over time
(p = .065) with higher NART associated with improvement of cognitive ability over time. After
adjusting for age and sex, a 10 point increase in NART was associated with an improvement of 2%
in ADL scores, but this effect was explained by NART's influence on contemporaneous cognitive
ability.
Conclusion: Our data support the hypothesis that cognitive reserve continues to have a limited
influence on cognition after AD has been diagnosed and thus, indirectly, has an impact on ADL.
Background
Cognitive loss resulting in impairment of activities of
daily living (ADL) is central to the diagnosis of Alzheimer
disease (AD) [1]. Cholinesterase inhibitors, which are
symptomatic treatments, aim to halt and reverse decline
in both cognitive abilities and ADL [2]. Evidence from
randomised clinical trials suggests that all available
cholinesterase inhibitors have similar, moderate benefi-
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cial effects on these outcomes [3]. However, not all
patients who take cholinesterase inhibitors benefit and
there are no reliable predictors of whom is more or less
likely to benefit from these drugs. Nevertheless, despite a
lack of evidence of particular patient groups that might
benefit most, evidence from longitudinal studies prior to
the pervasive use of cholinesterase inhibitors is able to
inform clinicians which patients might be at greatest risk
of decline if left untreated. Review of available studies
indicates that, paradoxically, people with AD who have a
greater pre-morbid cognitive reserve are those who suffer
the most rapid decline after diagnosis, at least in terms of
life expectancy [4]. This is in contrast to the observation
that increased cognitive reserve protects against the devel-
opment of AD [4]. It is hypothesised that a greater patho-
logical load is needed to produce the same severity of
dementia in those with increased cognitive reserve and
that dementia severity, itself, predicts rate of subsequent
decline [4]: the course of decline in this paradigm, linear
or non-linear, is not yet established. The precise biological
substrates that underpin cognitive reserve require further
elucidation but can be considered in terms of those asso-
ciated with neurodevelopment (e.g. white matter integrity
[5]) and those associated cognitive ageing (inflammation,
oxidative stress and apoptosis) [6]. Such substrates are
thought to relate both to 'passive' reserve (i.e. fixed struc-
tures) and 'active' reserve (i.e. the functional capacity of
the brain to remodel, reconfigure etc) [7].
There is a wide range of putative indices of cognitive
reserve [4], chief amongst which is pre-morbid IQ [7].
Although cognitive reserve is thought to have its primary
effect on cognitive ability, its impact on ADLs, which may
be secondary to its effect on cognition, is also important,
especially in the context of dementia [7]. ADL criteria may
be superior to brief screening tests in screening for AD in
people with low educational attainment [8] suggesting
that education, and hence cognitive reserve, may be less
closely associated with ADLs than with cognition. Despite
a paucity of relevant data, support for this hypothesis
comes from a study of nearly 500 people with AD in Ohio
where education, but not occupation, influenced rate of
cognitive decline, whilst neither education nor occupa-
tion affected rate of decline in ADLs [9].
One methodological limitation of using education as an
index of cognitive reserve is that, unlike pre-morbid IQ, it
typically has limited variance, especially in women. There
is evidence in healthy older people that higher actual pre-
morbid IQ is associated with better ADLs in old age, even
after adjusting for contemporaneous cognitive ability
[10]. However, pre-morbid IQ accounts for only around
2.5% of variance in ADL scores [10] compared with
around 50% of IQ measured in old age [11]. It is thus
unsurprising that any effects of education on ADL in older
people are difficult to detect compared to its effect on cog-
nitive test scores. The corollary of this is that investigation
into any effect of cognitive reserve in AD is likely to
require sensitive measures of cognitive reserve, such as
pre-morbid IQ, rather than coarser measures, such as edu-
cation and occupation, to have adequate power to detect
significant effects in all but the largest samples. Unfortu-
nately, AD samples in which pre-morbid IQ is available
are rare and researchers have to rely on proxy variables
that estimate pre-morbid IQ. But here the question arises
as to whether these proxy variables have, themselves, been
affected by the disease process.
The National Adult Reading Test (NART) [12] is com-
monly used to estimate pre-morbid IQ. Using childhood
mental ability scores collected for a Scottish national sur-
vey at age 11 in 1932 [13] the NART has been validated
both in a healthy sample [14] and in people with demen-
tia who form part of the cohort described in this study
[15]. NART estimated IQ (NARTIQ), together with age, is
a major predictor of Mini-Mental State Examination
(MMSE) scores in health [16], but also in dementia across
a wide range of severity [17]. However, its influence on
other cognitive tests and on ADL is unknown in people
with AD. It is unclear, for example, whether any associa-
tion diminishes as the disease progresses. If this were the
case, it might imply that cerebral reserve becomes less
important as AD becomes more severe and that any pro-
tective effect of cognitive reserve is lost over time. This
would provide an explanation for the paradoxical obser-
vation that people with greater cognitive reserve decline
more quickly once they are diagnosed with AD which oth-
erwise is explained by assuming that mortality is associ-
ated with the degree of neuropathology rather than the
clinical severity of dementia. In addition, quantifying rela-
tionships between NARTIQ and cognitive tests would
allow more accurate adjustment for pre-morbid IQ when
neuropsychological assessment forms part of the diagnos-
tic process.
Methods
Sample
The sample, described in detail elsewhere [17,18], com-
prised 659 (195 male, 464 females) consecutive patients
with probable AD treated at a tertiary referral memory
clinic. Diagnosis was made or reviewed according to
NINCDS-ADRDA criteria at the clinic and patients were
scored on a range of cognitive and functional independ-
ence measures at baseline (see below). Choice of
cholinesterase inhibitor drug was pragmatic depending
on whether twice daily compliance could be assured
(rivastigmine given) or only once daily (donepezil given).
Patients were treated for 26 weeks and then reassessed on
cognitive, ADL, behavioural and carer-rated global meas-
ures as described below. A small proportion of patients
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seen during the initial phase of the clinic were also tested
after 12 weeks of treatment. Response was judged at 26
weeks so that once we were happy that the tests could be
used repeatedly in our patients we no longer tested at
week 12. A multi-disciplinary team comprising two con-
sultant psychiatrists, a consultant physician, a neuropsy-
chologist, two nurses and a pharamacist decided whether
the patient had responded to treatment. In general
patients were considered as responders if cognitive scores
improved or were stable over 26 weeks. Responders were
continued on the same drug and underwent further
assessments at 52 weeks and 78 weeks after treatment ini-
tiation.
Measures
Cognitive testing comprised the MMSE (score range 0–30)
[16], the Hopkins Verbal Learning Test (HVLT) (range 0–
72) [19], Verbal Fluency Categorical (VF-Cat), totalling
the number of animals named, and Lexical (VF-Lex),
totalling 'F', 'A' and 'S', forms [20], and the Paired Associ-
ate Learning (PAL) and Delayed Matching to Sample
(DMTS) subtests from the Cambridge Neuropsychologi-
cal Test Automated Battery visual and working memory
battery [21]. Pre-morbid IQ was estimated with the NART
a test of ability to pronounce 50 irregularly spelt English
words [12]. Functional independence was measured on
the Instrumental Activities of Daily Living (IADL) scale
(range 0–32) [22] and Physical Self-Maintenance Scale
(PSMS) (range 0–24) [22] commonly used as outcome
measures in AD [23]. Unlike the cognitive tests, higher
IADL scores indicate impairment due to greater depend-
ency.
Statistical analyses
All statistical analyses were performed using the SPSS 14.0
statistical package. After initial data description, we used a
general mixed linear models approach similar to that
adopted for the analysis of several waves of cognitive data
in a study of healthy cognitive ageing that estimated the
effects of prior IQ [24]. This approach allows data to be
included from participants even when they have not
attended all waves. Dummy variables were produced to
signify which waves patients had attended so that any
effect of attendance on dependent variables – which was
likely given that only responders attended at weeks 52 and
78 – could be adjusted for. There were two data types: 1)
the response variables, cognitive test scores and ADL
scores that were measured at each wave; 2) and fixed
explanatory variables including NARTIQ. The six cogni-
tive test scores were treated as repeated measures at each
assessment wave for an underlying cognitive trait and
between waves as snapshots over a relatively short period.
Formally, the model was of the form y = Xβ + Zγ + ε where
X is the matrix of fixed effects, Z the matrix of random
effects, β the vector of fixed effects parameters, γ the vector
of random effects parameters and ε the vector of residual
error. Hence the mixed model was set up to test for effects
of fixed variables on an underlying cognitive trait derived
from variance common to all cognitive tests and stable
over time. The model could also test for effects of fixed
variables on change in this cognitive trait between waves.
Since such effects tested the interaction between fixed var-
iables and wave, statistical power to detect significant
effects was less than that to detect effects on the underly-
ing cognitive trait. Similarly the model could test for
effects of fixed variables between different cognitive tests.
Finally, the model could test for differential effects of fixed
variables on change with time between the cognitive tests.
Models were adjusted for age, sex and drug given as co-
variables.
This design allowed adjustment for the high inter-correla-
tion between cognitive tests and between waves whilst
allowing investigation of effects specific for each test or at
each wave after adjustment for the general effect. The
model adjusts for these inter-correlations by pre-specify-
ing contrast matrices related to the covariance structure of
the data. However, such contrast matrices cannot be
assumed a priori but, instead, the data have to be exam-
ined to determine which covariance structure fits best.
Goodness of fit is determined using standard information
criteria. Once the optimal covariance structure is deter-
mined, the effects of fixed variables can then be tested for.
Thus, using a restricted maximum likelihood method, we
compared different covariance structures for within sub-
ject residual errors to determine the optimal covariance
structure judged by -2 restricted log likelihood, Akaike
Information Criterion (AIC) and Schwarz's Bayesian
Information Criterion (BIC) measures for the model with
no factors or covariates entered. A heterogeneous autore-
gressive covariance structure was found to be optimal and
this was set for subsequent hypothesis testing of the fixed
effects. IADL and PSMS were treated similarly to the cog-
nitive test scores and considered to represent an underly-
ing ADL trait. A first order autoregressive covariance
structure was found to be optimal for ADL data. Finally, of
note is that for each hypothesis tested the denominator
degrees of freedom might have non-integer values since
these were derived by a Sattlethwaite approximation.
Results
Sample description
Four hundred and thirty-three (65.7%) of the sample
were treated with donepezil and 226 (34.3%) with
rivastigmine. Three hundred and fifty-five patients had
NARTIQ scored with a mean estimated pre-morbid IQ of
104.7 (standard deviation 18.5) and mean age 77.4 years
(standard deviation 7.1 years), 70% of whom were
women and 19% lived alone. Patients with NARTIQ
scores had significantly better scores on all the cognitive
BMC Psychiatry 2008, 8:27 http://www.biomedcentral.com/1471-244X/8/27
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tests than those who did not have NARTIQ scores (differ-
ences all p < .001 except PAL p = .011 and DMTS p = .008).
Mean cognitive test scores for all waves of assessment are
shown in Table 1 and mean IADL and PSMS scores in
Table 2. Failure to be assessed after 26 weeks treatment,
reflecting poor drug tolerance or concordance, was not
significantly associated with sex (χ2 = .52, p = .47), living
alone (χ2 = 2.55, p = .11), drug given (χ2 = .003, p = .96),
age (F = .87, p = .35), NARTIQ (F = 2.30, p = .13), baseline
MMSE (F = .63, p = .43), IADL score (F = .30, p = .58) or
PSMS score (F = .02, p = .90). Having a week 52 assess-
ment, indicative of positive response to cholinesterase
treatment, was not significantly associated with sex (χ2 =
.05, p = .83), drug given (χ2 = .00, p = 1.0), age (F = .23, p
= .63), NARTIQ (F = 2.61, p = .11), baseline MMSE (F =
1.22, p = .27). There was a trend for benefit for those
patients who did not live alone (Fisher's exact test p =
.053). Responders had significantly lower (better) base-
line IADL scores (mean 14.1 versus 16.1, F = 6.66, p =
.010) and PSMS scores (mean 6.8 versus 8.1, F = 12.21, p
= .001).
Effects of NARTIQ on cognition
NARTIQ had a significant main effect on the underlying
cognitive trait as measured repeatedly by the six cognitive
tests over the five waves of assessment (F1,245.7 = 77.2, p <
.001). NARTIQ also made a significant differential contri-
bution to the six cognitive tests (F5,157.5 = 18.68, p < .001)
and had a significant effect on the differential change in
cognitive test scores over time (F20,217.5 = 1.66, p = .043).
There was a statistical trend for an effect on the change in
the underlying cognitive trait over time (F4,243.0 = 2.24, p
= .065) with higher NARTIQ being associated with
improvement of cognitive ability up to 78 weeks. Age, but
not sex or drug given, also had significant effects on cog-
nition. There was a significant main effect (F1,320.6 = 7.68,
p = .006) and a differential effect between cognitive tests
(F5,228.0 = 3.16, p = .009), but no effects on change in cog-
nitive test scores over time. The model set mean age at
Table 1: Mean cognitive test scores at baseline (week 0) and after 12, 26, 52 and 78 weeks of cholinesterase inhibitor treatment for all 
patients and the sub-sample who had NARTIQ scores.
Test (week) N All patients Mean score Standard deviation N Patients with NARTIQ scores Mean score Standard deviation
MMSE(0) 626 19.3 5.8 346 20.7 4.9
HVLT(0) 601 9.2 4.9 342 10.0 5.0
VF-Cat(0) 604 7.8 4.3 344 8.7 4.4
VF-Lex(0) 604 22.0 13.1 342 24.8 13.5
PAL(0) 461 4.3 1.8 298 4.5 1.8
DMTS(0) 447 11.1 3.1 290 11.5 2.8
MMSE(12) 143 19.5 5.5 101 20.3 5.2
HVLT(12) 84 9.7 5.6 67 10.2 5.7
VF-Cat(12) 82 8.5 5.0 66 9.0 5.3
VF-Lex(12) 82 24.3 14.9 66 25.7 15.2
PAL(12) 70 4.2 1.7 59 4.1 1.7
DMTS(12) 71 10.8 2.9 58 11.0 2.9
MMSE(26) 259 19.0 5.6 162 19.7 5.5
HVLT(26) 250 9.5 4.6 157 9.9 4.9
VF-Cat(26) 248 7.6 4.2 158 8.1 4.5
VF-Lex(26) 248 23.2 12.5 158 24.8 12.5
PAL(26) 170 4.5 1.8 124 4.4 1.7
DMTS(26) 183 11.1 3.1 127 11.2 3.0
MMSE(52) 96 18.6 5.4 75 19.0 5.3
HVLT(52) 87 9.2 5.7 69 9.3 5.8
VF-Cat(52) 87 6.9 4.5 68 7.0 4.7
VF-Lex(52) 87 23.5 13.9 68 25.0 14.0
PAL(52) 76 4.4 1.6 62 4.3 1.6
DMTS(52) 75 10.9 2.8 58 10.7 2.8
MMSE(78) 43 19.2 5.5 33 19.6 5.7
HVLT(78) 38 9.9 6.2 20 10.3 6.3
VF-Cat(78) 39 7.6 4.7 31 7.9 5.0
VF-Lex(78) 39 25.1 13.6 31 26.9 13.5
PAL(78) 29 4.3 1.8 23 4.3 1.8
DMTS(78) 33 10.6 3.4 25 10.7 3.4
MMSE – Mini-Mental State Examination; HVLT – Hopkins Verbal Learning Test total score over six trials; V-Cat – Categorical Verbal Fluency; V-Lex 
– Lexical Verbal Fluency; PAL – Paired Associates Learning from CANTAB battery; DMTS – Delayed Matching to Sample stages from the CANTAB 
battery.
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77.3 years and for every additional 10 years overall cogni-
tive ability was 3.5% lower. Relative to MMSE, age had a
less adverse effect on PAL (0.6% per 10 years) but, in
order, an increasingly adverse effect on VF-cat (0.1% per
10 years), HVLT (0.1% per 10 years), DMTS (0.3% per 10
years) and VF-lex (0.3% per 10 years). Adjusting for age
and NARTIQ, there was no significant change in cognitive
ability over time (F4,254.0 = 1.85, p = .12), nor in differen-
tial change in cognitive ability between cognitive tests
over time (F20,226.0 = 1.06, p = .39).
The main effect of NARTIQ increased overall cognitive
ability by 2.7% for every 10 IQ points. Relative to MMSE,
NARTIQ had a more positive effect, in increasing order,
on VF-cat (0.1% per 10 points), HVLT (0.2% per 10
points), and VF-lex (0.6% per 10 points), but had a lesser
effect on DMTS (0.1% per 10 points) and least of all on
PAL (0.3% per 10 points). Figure 1 shows the differential
effect of NARTIQ on cognitive tests over time. MMSE,
HVLT, PAL and DMTS are essentially unaffected by NAR-
TIQ, but for those patients with higher NARTIQ scores,
VF-cat shows a dip at week 12 whilst VF-lex shows a steady
improvement.
Effects of NARTIQ on ADL
NARTIQ had a significant main effect on ADL as meas-
ured repeatedly by IADL and PSMS at baseline, week 26,
week 52 and week 78 of treatment (F1,114.6 = 5.69, p =
.019). NARTIQ also had a significant effect on change in
ADL over time (F3,62.4 = 4.13, p = .010). NARTIQ had no
significant differential effect on IADL compared with
PSMS (p = .27) or on differential change over time (p =
.11). Age and sex, but not drug given or living alone, also
had significant effects on ADL. In a model that included
NARTIQ, age and sex, women had significantly worse
ADL scores over all waves compared with men (mean 12.7
for women, 11.5 for men, F1,124.6 = 4.03, p = .047), with
significantly worse IADL scores (mean 17.7 for women,
15.4 for men on IADL and 8.6 for women and 8.7 for men
on PSMS, F1,148.5 = 15.09, p < .001) after adjusting for
other effects; there were no significant effects of sex on
change in ADL over time. There was a statistical trend for
increasing age to be associated with worse ADL (F1,117.8 =
3.09, p = .082), but no significant effect over time (p =
.34). Older people scored differentially worse on IADL
compared with PSMS (F1,143.0 = 4.82, p = .030) with a
trend for this to be attenuated over time (F3,56.4 = 2.63, p
= .059). After adjusting for age, sex and NARTIQ, there
was a significant deterioration in ADL scores over time
(F3,44.4 = 4.60, p = .007), more markedly for IADL rather
than PSMS (F3,58.2 = 3.90, p = .013).
After adjusting for age and sex, a 10 point increase in NAR-
TIQ was associated with an overall improvement of 2% in
ADL scores. In addition, for every 10 extra NARTIQ
points, there was an improvement of 2% in ADL scores
between baseline and week 78. To check whether the
effect of NARTIQ was explained by current rather than
pre-morbid cognitive ability, baseline MMSE score was
Table 2: Mean IADL and PSMS scores for all patients and the sub-sample who had NARTIQ scores at baseline (week 0) and after 26, 52 
and 78 weeks of cholinesterase inhibitor treatment; higher scores indicate greater dependency
Assessment N All patients Mean Standard deviation N Patients with NARTIQ Mean Standard deviation
IADL(0) 551 15.8 6.5 294 14.7 6.2
PSMS(0) 548 7.9 3.1 292 7.5 2.9
IADL(26) 238 17.3 5.9 146 16.9 5.9
PSMS(26) 237 8.5 3.0 146 8.3 2.8
IADL(52) 75 16.5 7.2 59 16.7 7.1
PSMS(52) 74 8.1 3.5 58 8.1 3.4
IADL(78) 46 18.0 6.1 39 18.0 6.5
PSMS(78) 46 8.5 2.7 39 8.4 2.8
Percentage change of cognitive test scores relative to DMTS p  10 points increase in NARTIQFigure 1
Percentage change of cognitive test scores relative 
to DMTS per 10 points increase in NARTIQ. MMSE – 
Mini-Mental State Examination; HVLT – Hopkins Verbal 
Learning Test total score over six trials; V-Cat – Categorical 
Verbal Fluency; V-Lex – Lexical Verbal Fluency; PAL – Paired 
Associates Learning from CANTAB battery; DMTS – 
Delayed Matching to Sample stages from the CANTAB bat-
tery.
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
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Week 0 Week
12
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introduced as an additional independent covariable into
the model. All of the significant effects of NARTIQ previ-
ously found became non-significant indicating that effects
of current cognitive ability on ADL in AD far outweigh
those of pre-morbid IQ.
Discussion
Pre-morbid IQ continues to influence a range of cognitive
tests after AD diagnosis. The effect size is modest, around
2.7% for every 10 IQ points, compared with its effect in
non-demented older people [14]. Unsurprisingly, the
effect is greater for verbal compared with non-verbal tests.
There was a trend for higher pre-morbid IQ to improve
performance on cognitive scores over time for most tests
relative to lower pre-morbid IQ, with higher pre-morbid
IQ being particularly associated with relative improve-
ment in lexical verbal fluency, though this may reflect a
relative lack of novelty on repeated testing. Being older
also has a detrimental effect on cognitive scores, even in
the presence of dementia, but has no effect on change in
cognitive ability over time. As expected, given the selec-
tion of responders to continue treatment, there was no
significant effect of treatment on cognitive change over
time. However, despite this cognitive stability, ADL scores
deteriorated, especially instrumental activities of daily liv-
ing. This may reflect a greater sensitivity of IADL to change
compared with PSMS. The effect size of pre-morbid IQ on
ADL scores was similar to that of its effect on cognition.
The effect size was similar to that seen cross-sectionally
[10]. Again, those with higher pre-morbid IQs seemed to
be relatively protected from any deterioration in ADL over
time. However, once the effect of contemporaneous cog-
nitive ability was adjusted for, pre-morbid IQ no longer
exerted a significant effect on ADL. Thus the effects of pre-
morbid IQ on ADL appear to be mediated via its effects on
current cognitive ability in AD. In this sample, younger
men scored significantly better on instrumental activities
of daily living, perhaps reflecting persisting social roles.
This effect was distinct from any effect of living alone, sug-
gesting that it could not be explained purely by the likeli-
hood of younger men having wives who were still alive. It
may, on the other hand, be a cohort effect of lower pre-
morbid prevalence of performing household tasks like
cooking and laundry in men who married before the end
of the Second World War.
The effect of pre-morbid IQ on cognition in this longitu-
dinal study was considerably less than its effect on MMSE
on a cross-sectional basis [17]. This is likely to reflect the
superior design of longitudinal studies that can adjust for
within-subject effects that might otherwise be attributed
to a stable trait such as pre-morbid IQ. Despite the mod-
erate effect size, its presence supports the persisting effect
of cognitive reserve on the absolute level of cognition, and
to a lesser extent the rate of cognitive decline, even in the
presence of a dementing illness. Cognitive reserve is also
important for ADL, but only inasmuch as it protects
against cognitive impairment. This contrasts with its effect
on the behavioural and psychological symptoms of
dementia where it is pre-morbid IQ rather than contem-
poraneous cognitive ability that is protective [25]. Our
data are consistent with those of Pavlik and colleagues
who followed up 478 AD patients over 3.2 years [26].
They investigated the effect of the American version of the
NART on MMSE and ADAS-Cog scores together with the
Clinical Dementia Rating Scale and found higher pre-
morbid IQ, but not education, protected against decline
on these global cognitive and functioning outcomes. By
contrast a study from the Baylor College of Medicine [27]
did not find such an effect on MMSE score decline, though
the sample was smaller and thus may have been under-
powered. Similarly Drachman and colleagues found few
significant effects on the rate of decline in AD despite
studying a wide range of predictor variables in a sample of
just 42 patients [28]. On the other hand Mortimer and
colleagues found a significant association between psy-
chotic symptoms and the rate of cognitive decline in a
sample of 65 patients [29]; we also reported a link
between psychotic symptoms and cognitive status in our
patients [25]. A Chicago study, which used a composite
measure of pre-morbid reading ability, also failed to find
a significant effect of this once other variables, including
race, were adjusted for [30].
Though longitudinal studies have advantages for estimat-
ing effect sizes, they often suffer from the effects of attri-
tion; Pavlik and colleagues also had over 90% attrition at
the fifth wave of observation [26]. Indeed, there was delib-
erate selection involved in this study. Mixed linear models
can adjust for such attrition to some degree because they
include data from all participants, not just those who had
observations made at every wave. Moreover, by using
dummy variables indicating presence or absence at any
wave, we could test for any attrition bias. There was none
for NARTIQ; that is, people with lower pre-morbid IQs
were no less likely to be assessed at week 26 (p = .13) or
to be responders (p = .11). This finding, though, needs to
be considered in the context of selection bias towards
higher cognitive test scores for those patients who had a
NARTIQ score. There were thus relatively fewer patients
with very low cognitive tests scores in the sample analysed
and thus it is possible that an attrition bias may have been
found if all patients had had a NARTIQ and been included
in the longitudinal study. Moreover, there was a selection
bias for ADL, with people who were better at instrumental
activities of daily living at baseline being more likely to be
considered as responding to drug treatment. Hence, lon-
gitudinal effects of pre-morbid IQ on ADL may be less cer-
tain in those who presented with a lower level of self care.
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In addition to attrition bias on ADL scores, the sample
had an estimated pre-morbid IQ a little above average.
However, given the mean age of the sample, this would be
expected given the association between lower childhood
IQ and shorter life expectancy [31]. The sample is also
selected because of the nature of referral pathways to a ter-
tiary clinic. Not only did the patients have to present to
their general practitioner, but then had to be referred to a
consultant and by the consultant to the memory treat-
ment centre. This process generally took some time and
thus patients who were deteriorating rapidly were unlikely
to have reached the clinic. It may be, therefore, that any
effects of cognitive reserve would have been less in
patients who did not reach the clinic. Another limitation
of the study is the range of cognitive tests. There were sev-
eral cognitive domains that were not specifically tested
that would be more or less influenced by cognitive reserve
in AD. In addition, there were a number of explanatory
factors that we did not take into account. Higher depres-
sion scores were associated with increased rate of decline
in 102 Catholic clergy with AD [32]. However, low mood
correlates with NARTIQ in AD patients [25], which was
not taken into account, so that their findings could be
explained by pre-morbid ability. One explanatory factor
that was not open to us to investigate was the effect of race
[30] because of the limited ethnic variation of Lothian res-
idents. Nor did we take into account apolipoprotein E ε 4
status which has been implicated as a predictor of decline
in AD [33]. These limitations indicate that further studies
in other samples that can consider other explanatory var-
iables would be useful.
Conclusion
Pre-morbid IQ is an index of cognitive reserve. Our data
support the hypothesis that cognitive reserve continues to
influence cognition after AD has been diagnosed and
thus, indirectly, has an impact on ADL. Not only does cog-
nitive reserve influence the absolute level of performance,
but it appears to ameliorate cognitive deterioration in AD
patients, especially on tests with a high verbal content.
The effect of cognitive reserve in AD is, however, fairly
limited. Nevertheless, the degree of cognitive reserve
requires consideration when making a diagnosis of AD
and, to a lesser extent, when considering the likely future
cognitive and ADL trajectories.
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